Boston Scientific CEO James Tobin meets with FDA officials today to discuss concerns over quality control issues at several of the device maker's facilities. Last week, the FDA delivered a stern rebuke to the company, saying it has failed to correct deficiencies despite repeated warnings. Some Wall Street analysts have speculated that the regulatory problems could delay Boston Scientific's acquisition of Guidant. Not surprisingly, the company is adopting a conciliatory tone in its statements about the matter, pledging to resolve any problems quickly.
- read this article from The New York Times